Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 2-30 is a variable region gene segment encoding the variable domain of the kappa light chain of immunoglobulins (antibodies)[1]. The encoded region participates in antigen recognition by contributing to the antigen binding site of the antibody, pairing with heavy chain variable regions to confer specificity and diversity. This gene segment is expressed in B lymphocytes, where, after V-J rearrangement and possible somatic hypermutation, it helps generate the diverse antibody repertoire essential for humoral immunity. IGKV2-30 is part of the immunoglobulin kappa locus on chromosome 2 and is classified as a variable region gene (not a receptor, enzyme, or druggable therapeutic target). It is not itself a direct therapeutic target, drug target, or disease driver, but it contributes genetically and structurally to the antigen-binding properties of antibodies[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 2-30 (IGKV2-30).